BLCO vs. RXST, STAA, WRBY, COO, APLS, MDGL, OPCH, DOCS, IONS, and MMSI
Should you be buying Bausch + Lomb stock or one of its competitors? The main competitors of Bausch + Lomb include RxSight (RXST), STAAR Surgical (STAA), Warby Parker (WRBY), Cooper Companies (COO), Apellis Pharmaceuticals (APLS), Madrigal Pharmaceuticals (MDGL), Option Care Health (OPCH), Doximity (DOCS), Ionis Pharmaceuticals (IONS), and Merit Medical Systems (MMSI). These companies are all part of the "medical" sector.
RxSight (NASDAQ:RXST) and Bausch + Lomb (NYSE:BLCO) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.
RxSight has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500.
RxSight has higher earnings, but lower revenue than Bausch + Lomb. RxSight is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.
In the previous week, Bausch + Lomb had 7 more articles in the media than RxSight. MarketBeat recorded 10 mentions for Bausch + Lomb and 3 mentions for RxSight. Bausch + Lomb's average media sentiment score of 1.59 beat RxSight's score of 0.29 indicating that RxSight is being referred to more favorably in the media.
78.8% of RxSight shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 9.4% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
RxSight received 12 more outperform votes than Bausch + Lomb when rated by MarketBeat users. Likewise, 66.67% of users gave RxSight an outperform vote while only 38.71% of users gave Bausch + Lomb an outperform vote.
Bausch + Lomb has a net margin of -7.81% compared to Bausch + Lomb's net margin of -44.01%. RxSight's return on equity of 3.60% beat Bausch + Lomb's return on equity.
RxSight currently has a consensus target price of $60.63, suggesting a potential downside of 1.53%. Bausch + Lomb has a consensus target price of $19.45, suggesting a potential upside of 27.15%. Given RxSight's higher possible upside, analysts clearly believe Bausch + Lomb is more favorable than RxSight.
Summary
RxSight beats Bausch + Lomb on 10 of the 18 factors compared between the two stocks.
Get Bausch + Lomb News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLCO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bausch + Lomb Competitors List
Related Companies and Tools
